Publikationen, an denen er mitarbeitet Laura Arribillaga Arangoa (18)

2020

  1. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens

    Journal for immunotherapy of cancer, Vol. 8, Núm. 1

2016

  1. T-and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates

    Gene Therapy, Vol. 23, Núm. 10, pp. 753-759

2013

  1. A fusion protein between streptavidin and the endogenous tlr4 ligand EDA targets biotinylated antigens to dendritic cells and induces t cell responses in vivo

    BioMed Research International, Vol. 2013

2012

  1. Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses

    Vaccine, Vol. 30, Núm. 18, pp. 2848-2858

  2. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin

    International Journal of Cancer, Vol. 131, Núm. 3, pp. 641-651

  3. The extradomain A of fibronectin (EDA) combined with poly(I: C) enhances the immune response to HIV-1 p24 protein and the protection against recombinant Listeria monocytogenes-Gag infection in the mouse model

    Vaccine, Vol. 30, Núm. 15, pp. 2564-2569

  4. The extradomain a of fibronectin enhances the efficacy of lipopolysaccharide defective Salmonella bacterins as vaccines in mice

    Veterinary Research, Vol. 43, Núm. 1

2011

  1. Therapeutic effect of a peptide inhibitor of TGF-β on pulmonary fibrosis

    Cytokine, Vol. 53, Núm. 3, pp. 327-333

2010

  1. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice

    Journal of Immunology, Vol. 185, Núm. 9, pp. 5150-5159

2009

  1. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein

    Journal of Hepatology, Vol. 51, Núm. 3, pp. 520-527

2008

  1. Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein

    Molecular Therapy, Vol. 16, Núm. 1, pp. 210-217

2007

  1. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40

    Antiviral Research, Vol. 74, Núm. 1, pp. 25-35

  2. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo

    Journal of Immunology, Vol. 178, Núm. 2, pp. 748-756

2005

  1. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus

    Vaccine, Vol. 23, Núm. 27, pp. 3493-3499

2003

  1. A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage

    Hepatology, Vol. 37, Núm. 2, pp. 461-470

  2. CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination

    Journal of Immunology, Vol. 171, Núm. 11, pp. 5931-5939

  3. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses

    Journal of Virology, Vol. 77, Núm. 20, pp. 10862-10871

2002

  1. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus

    Vaccine, Vol. 21, Núm. 3-4, pp. 202-210